Session 1: The science to inform our decision making

Where are we now, what are our key challenges?

Professor Jeremy Chapman

Westmead Hospital, Australia

Immunoregulation and tolerance

Dr. Stuart J. Knechtle

Emory University School of Medicine, USA

Session 2: Reviewing the clinical evidence – considering the role of calcineurin inhibitors

Can the early elimination of CNIs bring clinical benefits?

Dr. Matthew R. Weir

University of Maryland Hospital, Baltimore, Maryland, USA

Long-term maintenance with CNIs – an update

Professor Josep M. Campistol

Hospital Clinic, University of Barcelona, Spain

Can we eliminate both CNIs and steroids?

Professor Yvon Lebranchu

University Hospital of Tours, France

Session 3: New immunosuppressive agents in kidney transplantation

Considerations for new immunosuppressive combinations: A clinical perspective

Professor Lionel Rostaing

Toulouse University Hospital, France

Session 4: Post-transplant malignancy

Can immunosuppressive strategies be used to reduce the risk of cancer in renal transplant patients?

Professor Edward K. Geissler

University of Regensburg, Germany

Session 5: The non-immunosuppressive properties of mTOR-inhibition

Regression of left ventricular hypertrophy in kidney transplant recipients – the potential role for mTOR-inhibition

Dr. Ernesto Paoletti

San Martino University Hospital, Genoa, Italy

mTOR-inhibition and impact on autosomal dominant polycystic kidney disease

Professor Rudolf P. Wüthrich

University Hospital, Zürich, Switzerland

Session 6: Conclusions from the symposium

Conclusions from the symposium

Professor Josep M. Campistol

Hospital Clinic, University of Barcelona, Spain